. 2022 Jul 20;4(3):164–169. doi: 10.1097/BS9.0000000000000121

Table 2.

Univariate analysis of risk factors for CMV infection.

		CMV infection (N = 173)	Non-CMV infection (N = 186)	P value
Underlying diseases	AML	110	127	0.553
	ALL	57	55
	MAL	6	4
Gender	Male	96	102	0.901
Gender	Female	77	84	0.901
Risk stratification	High	78	88	0.673
Risk stratification	Standard	95	98	0.673
Disease status	Non-CR	15	25	0.151
Disease status	CR	158	161	0.151
Donor type	HRD	139	56	<0.001
Donor type	MSD	34	130	<0.001
Donor/recipient serostatus	D+/R+	153	158	0.166
	D−/R+	12	7
	D+/R−	3	8
TBI in conditioning regimen	Yes	42	42	0.704
TBI in conditioning regimen	No	131	144	0.704
ATG	Yes	157	82	<0.001
ATG	No	16	104	<0.001
MMF	Yes	109	53	<0.001
MMF	No	64	133	<0.001
MRD	Positive	47	60	0.292
MRD	Negative	126	126	0.292
Corticosteroid therapy in 30 d	Yes	145	83	<0.001
Corticosteroid therapy in 30 d	No	28	103	<0.001
GVHD in 30 d	Yes	36	24	0.045
GVHD in 30 d	No	137	162	0.045
Age (y)	Mean ± SD	33.93 ± 13.30	33.72 ± 13.33	0.878
Donor age (y)	Mean ± SD	37.02 ± 13.43	35.08 ± 12.55	0.157
MNC (×10⁸/kg)	Mean ± SD	10.87 ± 3.50	10.27 ± 3.30	0.097
CD34+ cells (×10⁶/kg)	Mean ± SD	3.20 ± 1.11	3.14 ± 1.68	0.691
Tregs in lymphocytes (%)	Mean ± SD	1.53 ± 2.62	2.11 ± 4.81	0.168
CD3+CD8+cells in lymphocytes (%)	Mean ± SD	15.25 ± 15.38	25.84 ± 14.60	<0.001

ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, ATG = antithymocyte globulin, BM = bone marrow, CMV = cytomegalovirus, CR = complete remission, GVHD = graft-versus-host disease, HRD = haploidentical-related donor, MAL = mixed acute leukemia, MMF = mycophenolate mofetil, MNC = mononuclear cell, MRD = minimal residual disease, MSD = matched sibling donor, PBSC = peripheral blood stem cell, TBI = total body irradiation, Tregs = regulatory T cells.